The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells

Pesticide Biochemistry and Physiology

Volumn 120, Issue , 2015, Pages 5-13

  Bekki, Kanae ^a   Vogel, Helena ^a   Li, Wen ^a   Ito, Tomohiro ^a   Sweeney, Colleen ^b   Haarmann Stemmann, Thomas ^c   Matsumura, Fumio ^a   Vogel, Christoph F A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IUF LEIBNIZ RESEARCH INSTITUTE FOR ENVIRONMENTAL MEDICINE   (Germany)

Author keywords

AhR; Apoptosis; Breast cancer; IDO; NF B; TCDD

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; CYCLOOXYGENASE 2; DOXORUBICIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 2, HUMAN; KYNURENINE; LAPATINIB; MESSENGER RNA; PACLITAXEL; POLYCHLORINATED DIBENZODIOXIN; PTGS2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; RELB PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELB;

APOPTOSIS; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; RADIATION RESPONSE; TUMOR CELL LINE; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DOXORUBICIN; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; PACLITAXEL; POLYCHLORINATED DIBENZODIOXINS; QUINAZOLINES; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELB; ULTRAVIOLET RAYS;

EID: 84929505017     PISSN: 00483575     EISSN: 10959939     Source Type: Journal    
DOI: 10.1016/j.pestbp.2014.12.021     Document Type: Article

References (42)

1. Trombino A.F., Near R.I., Matulka R.A., Yang S., Hafer L.J., Toselli P.A., et al. Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Res. Treat 2000, 63:117-131.
2. Brooks J., Eltom S.E. Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor. Curr. Cancer Drug Targets 2011, 11:654-669.
3. Chopra M., Schrenk D. Dioxin toxicity, aryl hydrocarbon receptor signaling, and apoptosis-persistent pollutants affect programmed cell death. Crit. Rev. Toxicol 2011, 41:292-320.
4. Park S., Matsumura F. Characterization of anti-apoptotic action of TCDD as a defensive cellular stress response reaction against the cell damaging action of ultra-violet irradiation in an immortalized normal human mammary epithelial cell line, MCF10A. Toxicology 2006, 217:139-146.
5. Fujisawa Y., Li W., Wu D., Wong P., Vogel C., Dong B., et al. Ligand-independent activation of the aryl hydrocarbon receptor by ETK (Bmx) tyrosine kinase helps MCF10AT1 breast cancer cells to survive in an apoptosis-inducing environment. Biol. Chem 2011, 10:897-908.
6. Pääjärvi G., Viluksela M., Pohjanvirta R., Stenius U., Högberg J. TCDD activates Mdm2 and attenuates the p53 response to DNA damaging agents. Carcinogenesis 2005, 26:201-208.
7. Chang X., Fan Y., Karyala S., Schwemberger S., Tomlinson C.R., Sartor M.A., et al. Ligand-independent regulation of transforming growth factor beta1 expression and cell cycle progression by the aryl hydrocarbon receptor. Mol. Cell. Biol 2007, 27:6127-6139.
8. Marlowe J.L., Fan Y., Chang X., Peng L., Knudsen E.S., Xia Y., et al. The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis. Mol. Biol. Cell 2008, 19:3263-3271.
9. Frauenstein K., Sydlik U., Tigges J., Majora M., Wiek C., Hanenberg H., et al. Evidence for a novel anti-apoptotic pathway in human keratinocytes involving the aryl hydrocarbon receptor, E2F1, and checkpoint kinase 1. Cell Death Differ 2013, 10:1425-1434.
10. Zou E., Matsumura F. Long-term exposure to beta-hexachlorocyclohexane (beta-HCH) promotes transformation and invasiveness of MCF-7 human breast cancer cells. Long-term exposure to beta-hexachlorocyclohexane (beta-HCH) promotes transformation and invasiveness of MCF-7 human breast cancer cells. Biochem. Pharmacol 2003, 66:831-840.
11. Wong P.S., Li W., Vogel C.F., Matsumura F. Characterization of MCF mammary epithelial cells overexpressing the arylhydrocarbon receptor (AhR). BMC Cancer 2009, 9:1-15.
12. Safe S., Astroff B., Harris M., Zacharewski T., Dickerson R., Romkes M., et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds as antioestrogens: characterization and mechanism of action. Pharmacol. Toxicol 1991, 69:400-409.
13. Fornier M.N., Morris P.G., Abbruzzi A., D'Andrea G., Gilewski T., Bromberg J., et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann. Oncol 2011, 22:2575-2581.
14. Vogel C.F., Li W., Wu D., Miller J.K., Sweeney C., Lazennec G., et al. Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression. Arch. Biochem. Biophys 2011, 512:78-86.
15. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol 2007, 18:977-984.
16. Dong B., Matsumura F. The conversion of rapid TCCD nongenomic signals to persistent inflammatory effects via select protein kinases in MCF10A cell. Mol. Endocrinol 2009, 23:549-558.
17. Forrest R.A., Swift L.P., Rephaeli A., Nudelman A., Kimura K., Phillips D.R., et al. Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochem. Pharmacol 2012, 83:1602-1612.
18. Sun X., Li D., Yang Y., Ren Y., Li J., Wang Z., et al. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity. J. Pathol 2012, 226:666-673.
19. Vogel C.F., Boerboom A.M., Baechle C., El-Bahay C., Kahl R., Degen G.H., et al. Regulation of prostaglandin endoperoxide H synthase-2 induction by dioxin in rat hepatocytes: possible c-Src-mediated pathway. Carcinogenesis 2000, 21:2267-2274.
20. Vogel C.F., Sciullo E., Park S., Liedtke C., Trautwein C., Matsumura F. Dioxin increases C/EBPbeta transcription by activating cAMP/protein kinase A. J. Biol. Chem 2004, 279:8886-8894.
21. Vogel C.F., Sciullo E., Li W., Wong P., Lazennec G., Matsumura F. RelB, a new partner of aryl hydrocarbon receptor-mediated transcription. Mol. Endocrinol 2007, 21:2941-2955.
22. Munn D.H., Mellor A.L. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J. Clin. Invest 2007, 117:1147-1154.
23. Vogel C.F., Goth S.R., Dong B., Pessah I.N., Matsumura F. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2, 3-dioxygenase. Biochem. Biophys. Res. Commun 2008, 375:331-335.
24. Soliman H., Rawal B., Fulp J., Lee J.H., Lopez A., Bui M.M., et al. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol. Immunother 2013, 62:829-837.
25. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med 2005, 11:312-319.
26. Denison M.S., Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol 2003, 43:309-334.
27. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov 2002, 1:609-620.
28. Pru J.K., Kaneko-Tarui T., Jurisicova A., Kashiwagi A., Selesniemi K., Tilly J.L. Induction of proapoptotic gene expression and recruitment of p53 herald ovarian follicle loss caused by polycyclic aromatic hydrocarbons. Reprod. Sci 2009, 16:347-356.
29. Davis J.W., Melendez K., Salas V.M., Lauer F.T., Burchiel S.W. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits growth factor withdrawal-induced apoptosis in the human mammary epithelial cell line, MCF-10A. Carcinogenesis 2000, 21:881-886.
30. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:493-501.
31. Matsumura F., Vogel C.F. Evidence supporting the hypothesis that one of the main functions of the aryl hydrocarbon receptor is mediation of cell stress responses. Biol. Chem 2006, 387:1189-1194.
32. Vogel C.F., Li W., Sciullo E., Newman J., Hammock B., Reader J.R., et al. Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. Am. J. Pathol 2007, 171:1538-1548.
33. Benoy I.H., Salgado R., Van Dam P., Geboers K., Van Marck E., Scharpé S., et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res 2004, 10:7157-7162.
34. Baud V., Jacque E. The alternative NF-kB activation pathway and cancer: friend or foe?. Med. Sci 2008, 24:1083-1088.
35. Murray I.A., Patterson A.D., Perdew G.H. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat. Rev. Cancer 2014, 14:801-814.
36. Markosyan N., Chen E.P., Smyth E.M. Targeting COX-2 abrogates mammary tumorigenesis: breaking cancer-associated suppression of immunosurveillance. Oncoimmunology 2014, 3:e29287.
37. Wu Y., Shen D., Chen Z., Clayton S., Vadgama J.V. Taxol induced apoptosis regulates amino acid transport in breast cancer cells. Apoptosis 2007, 12:593-612.
38. Lüpertz R., Wätjen W., Kahl R., Chovolou Y. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology 2010, 271:115-121.
39. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther 2001, 1:85-94.
40. Shao Z., Jiang M., Yu L., Han Q., Shen Z. p53 independent G1 arrest and apoptosis induced by adriamycin. Chin. Med. Sci. J. 1997, 12:71-75.
41. Sumikawa T., Shigeoka Y., Igishi T., Suyama H., Yamasaki A., Hashimoto K., et al. Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. Int. J. Oncol 2008, 32:683-688.
42. Santini R.P., Myrand S., Elferink C., Reiners J.J. Regulation of Cyp1a1 induction by dioxin as a function of cell cycle phase. J. Pharmacol. Exp. Ther 2001, 299:718-728.